Biological Activity of Soy Protein Hydrolysates Conjugated with Mannose and Allulose

A practical look at the research

If you formulate with plant protein, you already know the problem: hydrolysates bring bioactivity, but often at the cost of bitterness or limited functionality. Maillard conjugation is one way around that. This paper, published in Foods (DOI: 10.3390/foods13193041), tested what happens when soy protein hydrolysate is conjugated with mannose and allulose. The results are worth your attention.

Background

Peptides from soy protein can do useful things. They can act as antioxidants, inhibit enzymes, and support metabolic health. But their activity is often modest. The Maillard reaction — the same chemistry behind browning and flavor formation — can attach sugars to peptides without enzymes. That changes the structure of the peptides and, in many cases, improves their function. The catch is that common sugars like glucose and fructose bring their own metabolic baggage. Rare sugars such as allulose do not. This study asked whether conjugating soy peptides with mannose or allulose boosts bioactivity.

What the study did

The researchers conjugated soy protein hydrolysate with mannose and allulose using the Maillard reaction. They then measured three things: antioxidant capacity using DPPH and FRAP assays, pancreatic lipase inhibition, and ACE inhibition. ACE is the enzyme that regulates blood pressure. The authors also tested the rare sugars alone to see whether the sugar itself contributed any activity. This matters for formulators because a sugar that carries its own bioactivity could change how you dose the final ingredient.

Key findings

The allulose-conjugated soy protein hydrolysate (SPHA) stood out. Its DPPH radical scavenging activity reached 280.87 ± 16.39 µg Trolox/mL. Its FRAP value hit 38.91 ± 0.02 mg Trolox/mL. Both point to meaningful antioxidant capacity.

The lipase inhibition number is more modest but still interesting: 29.43 ± 1.94%. Pancreatic lipase is a target in weight-management ingredients. Inhibiting it reduces fat breakdown and absorption. A 29% inhibition from a peptide-sugar conjugate is not pharmaceutical level, but it is a real signal for a food-grade ingredient.

The abstract also reports ACE inhibitory properties. Both the conjugated mixtures and the rare sugars themselves showed ACE inhibition. That second part is notable. It suggests allulose is not just a passive carrier. It contributes to the effect.

Assay	SPHA result	What it suggests
DPPH radical scavenging	280.87 ± 16.39 µg Trolox/mL	Strong free-radical neutralization
FRAP	38.91 ± 0.02 mg Trolox/mL	Reducing power, antioxidant capacity
Pancreatic lipase inhibition	29.43 ± 1.94%	May help modulate fat digestion
ACE inhibition	Present (not quantified in abstract)	Potential blood-pressure modulation

What it means for manufacturers

This is early-stage data, but it points to a few practical directions.

First, allulose can do more than replace sugar. It can participate in protein chemistry. When you heat a protein hydrolysate with allulose, you get a conjugate with enhanced antioxidant properties. That could let you label a product as functional rather than just low-sugar.

Second, the lipase inhibition opens a door. If you need an ingredient for weight-management formulations, a soy peptide-allulose conjugate might offer dual function: metabolic support from allulose and enzyme inhibition from the peptide conjugate. The 29% figure is not dramatic, but it is real and dose-dependent in future work.

Third, ACE inhibition matters for heart-health positioning. Food ingredients with ACE-inhibitory activity are already common in the "foods for special medical purposes" space. Adding allulose conjugation as a tool could improve the potency of an existing soy peptide base.

One caveat: the study used in vitro assays. You cannot claim clinical effects from this paper alone. But you can use it as a screening rationale for your own product development.

FAQ

Does allulose itself show ACE inhibition? Yes. According to the abstract, the rare sugars tested had ACE inhibitory properties on their own. The conjugated mixtures did too. The abstract does not give exact numbers, so treat it as a qualitative signal.

Is this the same as Maillard browning that hurts protein quality? It is the same reaction, but with a different goal. Traditional food processing often tries to minimize Maillard reactions because they reduce lysine availability. Here, researchers intentionally drive the reaction to create new bioactive structures. The trade-off between amino acid modification and bioactivity gain needs to be evaluated in your specific ingredient.

Could this work with other plant proteins? The study only used soy. But the principle should transfer. Peanut, pea, and rice hydrolysates all contain reactive amino groups. If you work with those proteins, this paper is a strong reason to run your own conjugation trials with allulose.

Closing thought

Allulose is already valuable as a low-calorie sweetener. This paper suggests it can also function as a reactive partner in protein chemistry. For ingredient buyers, that means the allulose you source today may carry more functional potential than a simple sweetener spec sheet shows. For formulators, it means the next generation of bioactive protein ingredients may not require exotic enzymes or synthetic chemistry. Just heat, protein hydrolysate, and allulose.